Allogeneic versus syngeneic killer splenocytes as effector cells for the induction of graft-versus-tumor effect.

[1]  A. Diefenbach,et al.  Innate immune recognition by stimulatory immunoreceptors. , 2003, Current opinion in immunology.

[2]  Kazuyoshi Takeda,et al.  New aspects of natural-killer-cell surveillance and therapy of cancer , 2002, Nature Reviews Cancer.

[3]  M. Raffeld,et al.  Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.

[4]  R. Negrin,et al.  Studies of ex Vivo Activated and Expanded CD8+ NK-T Cells in Humans and Mice , 2002, Journal of Clinical Immunology.

[5]  S. Slavin,et al.  Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation. , 2002, Journal of hematotherapy & stem cell research.

[6]  Katia Perruccio,et al.  Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants , 2002, Science.

[7]  M. Martelli,et al.  Cellular therapy: exploiting NK cell alloreactivity in transplantation , 2001, Current opinion in hematology.

[8]  S. Slavin,et al.  Immunotherapy of relapsed resistant chronic myelogenous leukemia post allogeneic bone marrow transplantation with alloantigen pulsed donor lymphocytes , 2001, Bone Marrow Transplantation.

[9]  S. Slavin,et al.  Immunotherapy of cancer with alloreactive lymphocytes. , 2001, The Lancet. Oncology.

[10]  A. Nagler,et al.  Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen , 2001, Bone Marrow Transplantation.

[11]  W. Murphy,et al.  Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo. , 2001, Blood.

[12]  M. Smyth,et al.  Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (Trail) Contributes to Interferon γ–Dependent Natural Killer Cell Protection from Tumor Metastasis , 2001, The Journal of experimental medicine.

[13]  S. Slavin,et al.  Cell Therapy With Preimmunized Effector Cells Mismatched for Minor Histocompatible Antigens in the Treatment of a Murine Mammary Carcinoma , 2001, Journal of immunotherapy : official journal of the Society for Biological Therapy.

[14]  W. Seaman,et al.  Natural killer cells and natural killer T cells. , 2000, Arthritis and rheumatism.

[15]  S. Slavin,et al.  Allogeneic cell therapy in murine B-cell leukemia (BCL1): 2. The role of non-activated and rIL-2-activated CD4+ and CD8+ T cells in immunotherapy for leukemia. , 1999, Cytokines, cellular & molecular therapy.

[16]  W. M. Smit,et al.  Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. , 1999, Blood.

[17]  A. Diab,et al.  Allogeneic cell therapy for a murine mammary carcinoma. , 1998, Cancer research.

[18]  V. Dixit,et al.  Death receptors: signaling and modulation. , 1998, Science.

[19]  D. Taub,et al.  Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. , 1998, The Journal of clinical investigation.

[20]  S. Ostrand-Rosenberg,et al.  Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. , 1998, Cancer research.

[21]  G. Hortobagyi,et al.  Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  D. Longo,et al.  The potential role of NK cells in the separation of graft‐versus‐tumor effects from graft‐versus‐host disease after allogeneic bone marrow transplantation , 1997, Immunological reviews.

[23]  Robert H. Collins,et al.  Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  A. Nagler,et al.  Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. , 1995, Experimental hematology.

[25]  A Ferrant,et al.  Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. , 1995, Blood.

[26]  S. Crawford,et al.  Acute graft-versus-host disease and the risks for idiopathic pneumonia after marrow transplantation for severe aplastic anemia. , 1993, Bone marrow transplantation.

[27]  S. Steinberg,et al.  Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. , 1993, Journal of the National Cancer Institute.

[28]  W. Wilmanns,et al.  Donor Leukocyte Transfusions for Treatment of Recurrent Chronic Myelogenous Leukemia in Marrow Transplant Patients , 1990 .

[29]  S. Rosenberg,et al.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. , 1988, The New England journal of medicine.

[30]  H. Ljunggren,et al.  Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy , 1986, Nature.

[31]  S. Slavin,et al.  Functional clonal deletion versus active suppression in transplantation tolerance induced by total-lymphoid irradiation. , 1985, Transplantation.

[32]  K. Sullivan,et al.  Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. , 1981, The New England journal of medicine.

[33]  D. Dexter,et al.  Heterogeneity of tumor cells from a single mouse mammary tumor. , 1978, Cancer research.

[34]  R. Kiessling,et al.  „Natural”︁ killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype , 1975, European journal of immunology.

[35]  N. Breslow.  A generalized Kruskal-Wallis test for comparing K samples subject to unequal patterns of censorship , 1970 .

[36]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[37]  Rachel L. Mistur,et al.  Graft-Versus-Host Disease , 2016 .

[38]  J. Dorfman,et al.  The role of Ly49A and 5E6(Ly49C) molecules in hybrid resistance mediated by murine natural killer cells against normal T cell blasts. , 1996, Immunity.

[39]  J. Thompson,et al.  Interleukin-2 +/- lymphocytes as consolidative immunotherapy after autologous bone marrow transplantation for hematologic malignancies. , 1993, Acta haematologica.